Co-encapsulation of Docetaxel and Thymoquinone in mPEG-DSPE-Vitamin E TPGS-Lipid nanocapsules for breast cancer therapy: Formulation Optimization and Implications on cellular and in vivo toxicity.

Co-encapsulation of Docetaxel and Thymoquinone in mPEG-DSPE-Vitamin E TPGS-Lipid nanocapsules for breast cancer therapy: Formulation Optimization and Implications on cellular and in vivo toxicity. Eur J Pharm Biopharm. 2020 Jan 07;: Authors: Zafar S, Akhter S, Garg N, Selvapandiyan A, Kumar Jain G, Jalees Ahmad F Abstract Rationally designed combination nano-therapy approaches have emerged as a promising strategy for resistant breast cancer treatment. This research reports the combination of Docetaxel (DTX) and Thymoquinone (THQ) co-encapsulated within long circulating sub-100 nm mPEG-DSPE-Vitamin E TPGS-Lipid nanocapsules (DxTq-LNCs). DxTq-LNCs with sufficient drug loading exhibited controlled drug release, enhanced protein binding resistance (confirming its long circulation and suitability for iv application) and retained the antioxidant effects of THQ. DxTq-LNCs was further subjected to cytotoxicity analysis against human breast cancer cells (MCF7 & MDA-MB-231). The presence of multidrug resistance (MDR) reversal agents; Vitamin E TPGS and THQ, along with the nanoencapsulation, re-sensitized the resistant triple negative breast cancer (TNBC) cells to the anticancer effects of DTX. Greater inhibition of cell migration indicated improved anti-metastatic effects. Drastic changes in cellular morphology indicated by nuclear fragmentation (the hall marks of apoptosis), were observed upon DxTq-LNCs treatment to the breast cancer cell...
Source: European Journal of Pharmaceutics and Biopharmaceutics - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Biopharm Source Type: research